Induction of endogenous cytokine-mRNA in circulating peripheral blood mononuclear cells by IL-2 administration to cancer patients.
The DOI matches its Crossref record.
Abstract
The lymphokine IL-2 plays a central role in immune regulation. Recent clinical trials have shown that when administered systemically either alone, or in combination with lymphokine-activated killer cells, IL-2 can cause regression of metastatic tumors in some patients with a variety of otherwise refractory cancers. To evaluate the mechanism of in vivo action of IL-2, as well as the toxicity associated with its administration, we have studied the in vivo cytokine-mRNA expression of circulating PBMC in cancer patients undergoing treatment with high dose IL-2. Before IL-2 administration, we found low level or no evidence of cytokine-mRNA expression in PBMC. After IL-2 infusion, circulating PBMC showed enhanced proliferative activity and contained significant levels of mRNA for TNF-alpha and IL-6 as well as mRNA for the p55 IL-2R, Tac, but no mRNA coding for granulocyte-monocyte-CSF and TNF-beta (lymphotoxin). IL-1 beta mRNA was expressed at very low levels in circulating PBMC after IL-2 infusion. Each of these cytokine -mRNA was, however, inducible in vitro by stimulation of PBMC with IL-2 alone. The results of these in vivo studies suggest that IL-2 may be a physiologic inducer of TNF and IL-6 which, because of their pleiotropic effects, may be important endogenous signals in the body's immune response and account for some of the physiologic changes seen in patients receiving high dose IL-2.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
Biology and clinical relevance of human natural killer cells
Robertson, M., & Ritz, J. (1990) · Blood · doi:10.1182/blood.v76.12.2421.2421 · Cited by 931
Fibrogenic cytokines: the role of immune mediators in the development of scar tissue
Kovacs, E. J. (1991) · Immunology Today · doi:10.1016/0167-5699(91)90107-5 · Cited by 590
Hibbs, J. B., Westenfelder, C., Taintor, R., Vavrin, Z., Kablitz, C., Baranowski, R. L., Ward, J. H., Menlove, R. L., McMurry, M. P., & Kushner, J. P. (1992) · Journal of Clinical Investigation · doi:10.1172/jci115666 · Cited by 485
Le, J., & Vilček, J. (1990) · Pathology Reviews • 1990 · doi:10.1007/978-1-4612-0485-5_7 · Cited by 474
Natural history and therapy of metastatic renal cell carcinoma: The role of interleukin-2
Bukowski, R. M. (1997) · Cancer · doi:10.1002/(sici)1097-0142(19971001)80:7<1198::aid-cncr3>3.0.co;2-h · Cited by 325
Caligiuri, M. A., Murray, C., Robertson, M. J., Wang, E., Cochran, K., Cameron, C., Schow, P., Ross, M. E., Klumpp, T. R., & Soiffer, R. J. (1993) · Journal of Clinical Investigation · doi:10.1172/jci116161 · Cited by 269
Forecasting the cytokine storm following systemic interleukin (IL)-2 administration
Panelli, M. C., White, R., Foster, M., Martin, B., Wang, E., Smith, K., & Marincola, F. M. (2004) · Journal of Translational Medicine · doi:10.1186/1479-5876-2-17 · Cited by 139
“Although, it has been postulated that IL-2 acts through the in vivo expansion and activation of cytotoxic T lymphocytes [1] and/or the promotion of their migration within target tissues [3], it is likely that at the pharmacologic doses used therapeutically IL-2 has broader immune/pro-inflammatory effects [4,5].”
BackgroundThe Local Effects of Cachectin/Tumor Necrosis Factor on Wound Healing
SALOMON, G. D., KASID, A., CROMACK, D. T., DIRECTOR, E., TALBOT, T. L., SANK, A., & NORTON, J. A. (1991) · Annals of Surgery · doi:10.1097/00000658-199108000-00012 · Cited by 84
Self-citation
Metadata
- Authors
- Kasid, A., Director, E. P., & Rosenberg, S. A.
- Venue
- The Journal of Immunology
- Publisher
- Oxford University Press (OUP)
- Published
- 1989-07
- Volume
- 143
- Issue
- 2
- Pages
- 736-739
- ISSN
- 0022-1767 (ISSN-L)
- 1550-6606
- OpenAlex
- W1631971313
- Cited by
- 92
- References
- 0
- FWCI
- 5.76
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.